Gene therapy for RPE65-related retinal disease

被引：93

作者：

Utz, Virginia Miraldi ^{[1
,2
]}

Coussa, Razek Georges ^{[3
]}

Antaki, Fares ^{[4
]}

Traboulsi, Elias, I ^{[3
]}

机构：

[1] Cincinnati Childrens Hosp Med Ctr, Abrahamson Pediat Eye Inst, Cincinnati, OH 45229 USA

[2] Univ Cincinnati, Dept Ophthalmol, Cincinnati, OH USA

[3] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA

[4] Univ Montreal, Dept Ophthalmol, Montreal, PQ, Canada

来源：

OPHTHALMIC GENETICS | 2018年 / 39卷 / 06期

关键词：

RPE65; gene therapy; Leber Congenital Amaurosis; voretigine neparvovec; clinical trials; LEBER CONGENITAL AMAUROSIS; MOLECULAR-GENETICS; CLINICAL-FEATURES; DOMINANT MUTATION; RPE65; MUTATIONS; VISUAL CYCLE; SAFETY; DYSTROPHY; VISION; EFFICACY;

D O I：

10.1080/13816810.2018.1533027

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Significant discoveries in the etiology and pathogenesis of inherited retinal diseases (IRDs) have been made in the last few decades. Of the large number genes that cause IRDs, bi-allelic mutations in RPE65 lead to Leber Congenital Amaurosis type 2 (LCA 2), and can also result in phenotypes described as severe early childhood onset retinal dystrophy (SECORD) and Retinitis pigmentosa 20 (RP20). Following the publication of the successful Phase-III clinical trials of gene augmentation surgery for RPE65-related IRDs with voretigene neparvovec, the FDA approved the commercial use of this pharmacologic agent in December 2017. In this perspective, ongoing and completed gene therapy trials for RPE65-related dystrophies are reviewed and challenges in patient selection, counseling and informed consent, as well as financial considerations of commercial treatment are discussed.

引用

页码：671 / 677

页数：7

共 41 条

[11] Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics [J].

Cideciyan, Artur V. ;

Aleman, Tomas S. ;

Boye, Sanford L. ;

Schwartz, Sharon B. ;

Kaushal, Shalesh ;

Roman, Alejandro J. ;

Pang, Ji-Jing ;

Sumaroka, Alexander ;

Windsor, Elizabeth A. M. ;

Wilson, James M. ;

Flotte, Terence R. ;

Fishman, Gerald A. ;

Heon, Elise ;

Stone, Edwin M. ;

Byrne, Barry J. ;

Jacobson, Samuel G. ;

Hauswirth, William W. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (39) :15112-15117

[12] Leber congenital amaurosis, from darkness to light: An ode to Irene Maumenee [J].

Coussa, Razek Georges ;

Solache, Irma Lopez ;

Koenekoop, Robert K. .

OPHTHALMIC GENETICS, 2017, 38 (01) :7-15

[13] Molecular genetics of Leber congenital amaurosis [J].

Cremers, FPM ;

van den Hurk, JAJM ;

den Hollander, AI .

HUMAN MOLECULAR GENETICS, 2002, 11 (10) :1169-1176

[14] From the Laboratory to the Clinic: Molecular Genetic Testing in Pediatric Ophthalmology [J].

Drack, Arlene V. ;

Lambert, Scott R. ;

Stone, Edwin M. .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 2010, 149 (01) :10-17

[15] Which Leber congenital amaurosis patients are eligible for gene therapy trials? [J].

Drack, Arlene V. ;

Johnston, Rebecca ;

Stone, Edwin M. .

JOURNAL OF AAPOS, 2009, 13 (05) :463-465

[16] Vision in leber congenital amaurosis [J].

Fulton, AB ;

Hansen, RM ;

Mayer, DL .

ARCHIVES OF OPHTHALMOLOGY, 1996, 114 (06) :698-703

[17] Treatment of Leber Congenital Amaurosis Due to RPE65 Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial [J].

Hauswirth, William W. ;

Aleman, Tomas S. ;

Kaushal, Shalesh ;

Cideciyan, Artur V. ;

Schwartz, Sharon B. ;

Wang, Lili ;

Conlon, Thomas J. ;

Boye, Sanford L. ;

Flotte, Terence R. ;

Byrne, Barry J. ;

Jacobson, Samuel G. .

HUMAN GENE THERAPY, 2008, 19 (10) :979-990

[18]

HEHER KL, 1992, OPHTHALMOLOGY, V99, P241

[19]

Hull S, 2016, MOL VIS, V22, P626

[20]

Institute for Clinical and Economic Review, 2018, VORT NEP BIALL RPE65

← 1 2 3 4 5 →